Loading...

BioLife Solutions

DB:BJX1
Snowflake Description

High growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BJX1
DB
$331M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

BioLife Solutions, Inc. develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. The last earnings update was 14 days ago. More info.


Add to Portfolio Compare Print
BJX1 Share Price and Events
7 Day Returns
5.4%
DB:BJX1
0%
DE Medical Equipment
-0.6%
DE Market
1 Year Returns
114.8%
DB:BJX1
15.1%
DE Medical Equipment
-10.8%
DE Market
BJX1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioLife Solutions (BJX1) 5.4% 14.1% 2.6% 114.8% 1058.6% -
DE Medical Equipment 0% 1.2% 5.6% 15.1% 105% 232.1%
DE Market -0.6% -3.3% 2.3% -10.8% 8% 8%
1 Year Return vs Industry and Market
  • BJX1 outperformed the Medical Equipment industry which returned 15.1% over the past year.
  • BJX1 outperformed the Market in Germany which returned -10.8% over the past year.
Price Volatility
BJX1
Industry
5yr Volatility vs Market

BJX1 Value

 Is BioLife Solutions undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BioLife Solutions to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for BioLife Solutions.

DB:BJX1 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:BJX1
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.9
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.895 (1 + (1- 21%) (0.5%))
0.932
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.93
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.932 * 5.96%)
5.78%

Discounted Cash Flow Calculation for DB:BJX1 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for BioLife Solutions is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:BJX1 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.78%)
2019 3.00 Analyst x1 2.84
2020 6.70 Analyst x1 5.99
2021 9.70 Analyst x1 8.19
2022 12.19 Est @ 25.7% 9.74
2023 14.39 Est @ 18.06% 10.87
2024 16.22 Est @ 12.71% 11.58
2025 17.68 Est @ 8.96% 11.93
2026 18.80 Est @ 6.34% 11.99
2027 19.65 Est @ 4.51% 11.84
2028 20.28 Est @ 3.22% 11.56
Present value of next 10 years cash flows $96.51
DB:BJX1 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $20.28 × (1 + 0.23%) ÷ (5.78% – 0.23%)
$365.81
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $365.81 ÷ (1 + 5.78%)10
$208.48
DB:BJX1 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $96.51 + $208.48
$304.99
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $304.99 / 18.80
$16.22
DB:BJX1 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:BJX1 represents 0.93318x of NasdaqCM:BLFS
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.93318x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 16.22 x 0.93318
€15.14
Value per share (EUR) From above. €15.14
Current discount Discount to share price of €16.45
= -1 x (€16.45 - €15.14) / €15.14
-8.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of BioLife Solutions is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioLife Solutions's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioLife Solutions's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:BJX1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $0.20
NasdaqCM:BLFS Share Price ** NasdaqCM (2019-05-23) in USD $17.63
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 35.3x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 20.28x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioLife Solutions.

DB:BJX1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:BLFS Share Price ÷ EPS (both in USD)

= 17.63 ÷ 0.20

88.71x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioLife Solutions is overvalued based on earnings compared to the DE Medical Equipment industry average.
  • BioLife Solutions is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does BioLife Solutions's expected growth come at a high price?
Raw Data
DB:BJX1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 88.71x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
53.9%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 3.07x
Germany Market PEG Ratio Median Figure of 271 Publicly-Listed Companies 1.51x

*Line of best fit is calculated by linear regression .

DB:BJX1 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 88.71x ÷ 53.9%

1.65x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioLife Solutions is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on BioLife Solutions's assets?
Raw Data
DB:BJX1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $2.37
NasdaqCM:BLFS Share Price * NasdaqCM (2019-05-23) in USD $17.63
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.18x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.78x
DB:BJX1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:BLFS Share Price ÷ Book Value per Share (both in USD)

= 17.63 ÷ 2.37

7.44x

* Primary Listing of BioLife Solutions.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioLife Solutions is overvalued based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess BioLife Solutions's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. BioLife Solutions has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BJX1 Future Performance

 How is BioLife Solutions expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
53.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioLife Solutions expected to grow at an attractive rate?
  • BioLife Solutions's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • BioLife Solutions's earnings growth is expected to exceed the Germany market average.
  • BioLife Solutions's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:BJX1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:BJX1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 53.9%
DB:BJX1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 34.8%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 12.6%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.2%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:BJX1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:BJX1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 126 68 1
2022-12-31 90 43 1
2021-12-31 56 11 18 2
2020-12-31 40 7 10 3
2019-12-31 29 4 4 3
DB:BJX1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 22 3 3
2018-12-31 20 2 3
2018-09-30 17 3 1
2018-06-30 15 2 0
2018-03-31 12 1 -2
2017-12-31 11 1 -3
2017-09-30 10 -1 -5
2017-06-30 9 -2 -6
2017-03-31 9 -3 -7
2016-12-31 8 -4 -7
2016-09-30 8 -5 -5
2016-06-30 7 -5 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BioLife Solutions's earnings are expected to grow significantly at over 20% yearly.
  • BioLife Solutions's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:BJX1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from BioLife Solutions Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BJX1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.57 2.57 2.57 1.00
2022-12-31 1.65 1.65 1.65 1.00
2021-12-31 0.71 0.99 0.42 2.00
2020-12-31 0.38 0.54 0.30 3.00
2019-12-31 0.15 0.18 0.11 3.00
DB:BJX1 Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 0.20
2018-12-31 0.18
2018-09-30 0.09
2018-06-30 -0.01
2018-03-31 -0.14
2017-12-31 -0.21
2017-09-30 -0.41
2017-06-30 -0.46
2017-03-31 -0.51
2016-12-31 -0.54
2016-09-30 -0.37
2016-06-30 -0.39

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • BioLife Solutions is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess BioLife Solutions's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioLife Solutions has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BJX1 Past Performance

  How has BioLife Solutions performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioLife Solutions's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioLife Solutions has delivered over 20% year on year earnings growth in the past 5 years.
  • BioLife Solutions has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • BioLife Solutions has become profitable in the last year making it difficult to compare the DE Medical Equipment industry average.
Earnings and Revenue History
BioLife Solutions's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioLife Solutions Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BJX1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 21.70 3.46 9.65 1.32
2018-12-31 19.74 2.93 8.57 1.30
2018-09-30 17.42 1.43 7.94 1.28
2018-06-30 15.09 -0.15 7.37 1.26
2018-03-31 12.47 -1.96 6.96 1.25
2017-12-31 11.02 -2.73 6.61 1.19
2017-09-30 10.14 -5.39 6.41 1.33
2017-06-30 9.31 -5.93 6.66 1.53
2017-03-31 8.74 -6.52 7.15 1.81
2016-12-31 8.23 -6.88 7.60 2.03
2016-09-30 7.80 -4.67 8.15 2.03
2016-06-30 7.29 -4.77 8.24 1.86
2016-03-31 6.80 -4.41 7.80 1.56
2015-12-31 6.45 -4.21 7.45 1.38
2015-09-30 6.30 -4.01 6.98 1.31
2015-06-30 5.91 -3.80 6.35 1.13
2015-03-31 5.63 -3.69 5.92 1.03
2014-12-31 6.19 -3.22 5.30 0.87
2014-09-30 6.81 -2.79 4.73 0.64
2014-06-30 7.74 -2.24 4.26 0.65
2014-03-31 8.85 -1.64 3.84 0.55
2013-12-31 8.95 -1.08 3.56 0.49
2013-09-30 8.71 -1.11 3.43 0.47
2013-06-30 8.22 -1.15 3.23 0.42
2013-03-31 6.99 -1.37 3.05 0.45
2012-12-31 5.66 -1.66 2.77 0.46
2012-09-30 4.42 -1.56 2.36 0.48
2012-06-30 3.46 -1.69 2.29 0.47

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • BioLife Solutions has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • BioLife Solutions used its assets less efficiently than the DE Medical Equipment industry average last year based on Return on Assets.
  • BioLife Solutions has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess BioLife Solutions's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioLife Solutions has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BJX1 Health

 How is BioLife Solutions's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioLife Solutions's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioLife Solutions is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BioLife Solutions's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BioLife Solutions's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 23.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioLife Solutions Company Filings, last reported 1 month ago.

DB:BJX1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 44.37 1.66 31.82
2018-12-31 43.15 0.00 30.66
2018-09-30 43.93 0.00 32.38
2018-06-30 19.66 0.00 14.17
2018-03-31 10.47 0.00 7.03
2017-12-31 10.09 0.00 6.66
2017-09-30 7.21 0.00 2.83
2017-06-30 6.82 0.00 2.31
2017-03-31 2.80 3.94 2.29
2016-12-31 3.17 2.84 1.41
2016-09-30 6.59 1.75 1.37
2016-06-30 7.55 0.66 1.32
2016-03-31 8.53 0.00 1.66
2015-12-31 9.86 0.00 3.82
2015-09-30 10.78 0.00 5.25
2015-06-30 11.88 0.00 6.85
2015-03-31 12.85 0.00 8.58
2014-12-31 13.94 0.00 9.94
2014-09-30 12.67 0.00 11.02
2014-06-30 13.40 0.00 11.91
2014-03-31 14.08 0.00 12.84
2013-12-31 -13.27 10.60 0.16
2013-09-30 -12.86 10.60 0.08
2013-06-30 -12.66 10.60 0.08
2013-03-31 -12.40 10.60 0.06
2012-12-31 -12.49 10.60 0.20
2012-09-30 -12.04 10.60 0.01
2012-06-30 -11.74 10.60 0.16
  • BioLife Solutions's level of debt (3.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 3.7% today).
  • Debt is well covered by operating cash flow (187.1%, greater than 20% of total debt).
  • BioLife Solutions earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess BioLife Solutions's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioLife Solutions has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BJX1 Dividends

 What is BioLife Solutions's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BioLife Solutions dividends.
If you bought €2,000 of BioLife Solutions shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BioLife Solutions's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BioLife Solutions's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:BJX1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:BJX1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BioLife Solutions has not reported any payouts.
  • Unable to verify if BioLife Solutions's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BioLife Solutions's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BioLife Solutions has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BioLife Solutions's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioLife Solutions afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioLife Solutions has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BJX1 Management

 What is the CEO of BioLife Solutions's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Rice
COMPENSATION $691,397
AGE 55
TENURE AS CEO 12.8 years
CEO Bio

Mr. Michael P. Rice, also known as Mike, has been Chief Executive Officer and President of BioLife Solutions, Inc. since August 2006. Mr. Rice has more than 30 years of leadership and entrepreneurial experience in the medical and high tech industries. He served as Principal Financial and Accounting Officer of BioLife Solutions, Inc since February 25, 2016. He served as the Chief Financial Officer of Biolife Solutions Inc. He served as Development Manager of Business and Manager of Medical Industry Marketing and of Ami Semiconductor Inc. since November 29, 2004. He was the Senior Business Development Manager for Medical and Wireless Products at AMI Semiconductor from October 2004 to August 2006. He worked with Ami Semiconductor Inc. integrated mixed-signal and structured digital business units to create business opportunities in the medical sector. He worked closely with existing and potential customers to ensure that AMIS has a clear leadership product position with all major medical device manufacturers. From May 1998 to October 2000, he was the Vice President of Sales and Marketing for TEGRIS Corporation. From October 2000 to August 2006, he also served as the Director of Marketing and Business Development at Cardiac Science, Inc. He spent 12 years, from May 1986 to May 1998 at Physio Control Corporation in several sales and marketing roles prior to its acquisition by Medtronic Inc. He served as the Chairman of the Board at BioLife Solutions, Inc. from August 2007 to November 9, 2013. He has been a Director of Biolife Solutions, Inc. since August 2006. Mr. Rice studied Bachelor's degree in Business Administration from Bellevue, WA-based City University.

CEO Compensation
  • Mike's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Mike's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the BioLife Solutions management team in years:

4.3
Average Tenure
56.5
Average Age
  • The tenure for the BioLife Solutions management team is about average.
Management Team

Mike Rice

TITLE
President
COMPENSATION
$691K
AGE
55
TENURE
12.8 yrs

Roderick de Greef

TITLE
CFO & Secretary
COMPENSATION
$490K
AGE
58
TENURE
3 yrs

Aby Mathew

TITLE
Chairman of Scientific Advisory Board
COMPENSATION
$511K
AGE
46
TENURE
8.3 yrs

Karen Foster

TITLE
Vice President of Operations
AGE
58
TENURE
3.1 yrs

Kevin O'Donnell

TITLE
Vice President of Cold Chain Standards
TENURE
4.4 yrs

Todd Berard

TITLE
Vice President of Marketing
AGE
49
TENURE
4.3 yrs

Jim Mathers

TITLE
Vice President of Global Sales
AGE
59
TENURE
3 yrs
Board of Directors Tenure

Average tenure and age of the BioLife Solutions board of directors in years:

11.7
Average Tenure
56
Average Age
  • The average tenure for the BioLife Solutions board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Ray Cohen

TITLE
Non-Executive Chairman
COMPENSATION
$240K
AGE
59
TENURE
5.5 yrs

Mike Rice

TITLE
President
COMPENSATION
$691K
AGE
55
TENURE
12.8 yrs

Aby Mathew

TITLE
Chairman of Scientific Advisory Board
COMPENSATION
$511K
AGE
46

Andy Hinson

TITLE
Independent Director & Member of the Scientific Advisory Board
COMPENSATION
$115K
AGE
55
TENURE
12.3 yrs

Joe Schick

TITLE
Independent Director
COMPENSATION
$120K
AGE
57
TENURE
5.5 yrs

Thomas Girschweiler

TITLE
Director
COMPENSATION
$110K
AGE
61
TENURE
4 yrs

Dayong Gao

TITLE
Member of Scientific Advisory Board
TENURE
12.6 yrs

Shelly Heimfeld

TITLE
Member of Scientific Advisory Board
TENURE
12.6 yrs

Erik Woods

TITLE
Member of Scientific Advisory Board
TENURE
11.7 yrs

Scott Burger

TITLE
Member of Scientific Advisory Board
TENURE
11.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
14. Dec 18 Sell Andrew Hinson Individual 13. Dec 18 13. Dec 18 -4,000 €10.61 €-42,450
24. Aug 18 Sell Joseph Schick Individual 24. Aug 18 24. Aug 18 -4,765 €22.34 €-106,434
23. Aug 18 Sell Raymond Cohen Individual 21. Aug 18 21. Aug 18 -10,000 €20.54 €-205,448
14. Aug 18 Sell Raymond Cohen Individual 13. Aug 18 13. Aug 18 -10,000 €17.26 €-172,611
09. Jul 18 Sell Thomas Girschweiler Individual 09. Jul 18 09. Jul 18 -285,714 €9.68 €-2,765,181
09. Jul 18 Sell Walter Villiger Individual 09. Jul 18 09. Jul 18 -214,286 €9.68 €-2,073,891
06. Jun 18 Sell Joseph Schick Individual 01. Jun 18 01. Jun 18 -6,858 €8.63 €-59,169
01. Jun 18 Sell Raymond Cohen Individual 30. May 18 30. May 18 -10,000 €8.72 €-87,249
X
Management checks
We assess BioLife Solutions's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioLife Solutions has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BJX1 News

Simply Wall St News

BJX1 Company Info

Description

BioLife Solutions, Inc. develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death. The company offers CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing; and HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 to cryopreserve stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including cell and gene therapy companies, research institutions, hospital-based stem cell transplant centers, cell therapy contract manufacturing organizations, contract development manufacturing organizations, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

Details
Name: BioLife Solutions, Inc.
BJX1
Exchange: DB
Founded: 1987
$296,798,408
18,799,386
Website: http://www.biolifesolutions.com
Address: BioLife Solutions, Inc.
3303 Monte Villa Parkway,
Suite 310,
Bothell,
Washington, 98021,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM BLFS Common Stock Nasdaq Capital Market US USD 22. Nov 1989
DB BJX1 Common Stock Deutsche Boerse AG DE EUR 22. Nov 1989
Number of employees
Current staff
Staff numbers
54
BioLife Solutions employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 22:21
End of day share price update: 2019/05/23 00:00
Last estimates confirmation: 2019/05/22
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.